Trackins (Trk-Targeting Drugs): A Novel Therapy for Different Diseases
George N Chaldakov1, Luigi Aloe2, Stanislav G Yanev3
1Departments of Anatomy and Cell Biology and Translational Stem Cell Biology, Research Institute, Medical University, 9002 Varna, Bulgaria.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
Summary
Therapeutic strategies targeting neurotrophin receptors (Trk) offer new hope for reversing disease. "Trackins" (Trk-targeting drugs) show promise for cardiometabolic and neurodegenerative diseases, as well as cancers.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Cellular signaling pathways involving protein kinases and phosphatases regulate cell growth and function.
- Neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), play critical roles in neuronal survival, growth, and function.
- Dysregulation of neurotrophin signaling is implicated in various diseases, including cardiometabolic disorders and neurodegenerative conditions.
Purpose of the Study:
- To update and expand the concept of "trackins" (Trk-targeting drugs) for therapeutic intervention.
- To explore the potential of agonistic trackins for treating neurotrophin-deficiency related cardiometabolic and neurodegenerative diseases.
- To investigate the utility of antagonistic trackins, specifically TrkA(NGF) inhibitors, for treating cancers, pain, and cardiac arrhythmias.
Main Methods:
- Review and synthesis of published research on neurotrophins and their Trk receptors.
- Analysis of the role of specific neurotrophin-Trk interactions in disease pathogenesis.
- Conceptual framework development for "trackins" as therapeutic agents.
Main Results:
- Agonistic trackins show potential for treating conditions like hypertension, type 2 diabetes mellitus, Alzheimer's disease, and Parkinson's disease.
- Antagonistic trackins, particularly TrkA(NGF) inhibitors, are promising for prostate cancer, breast cancer, pain management, and arrhythmogenic right-ventricular dysplasia.
- The druggability of TrkA(NGF), TrkA(pro-NGF), TrkB(BDNF), and TrkC(NT-3) receptors via trackins is supported by existing data.
Conclusions:
- Trackins represent a novel class of drugs targeting Trk receptors for diverse therapeutic applications.
- Further translational research is warranted to fully realize the clinical potential of trackins in treating cardiometabolic, neurodegenerative, and oncological diseases.
- Targeting neurotrophin receptor pathways offers a promising avenue for developing effective therapies to reverse disease phenotypes.
Keywords:
Alzheimer’s diseaseBDNFNGFNT-3Trk receptorsTrk-targeting drugs (trackins)cancercardiometabolic diseasespainproNGFMore Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
7.9K
10:04Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
Published on: March 13, 2018
12.0K
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:26Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
01:28Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
01:26Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:24Principles of Drug Action
5.9K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.9K